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Abstract
The COVID-19 pandemic has presented unique challenges for the clinical trial community, both in the rapid
establishment of COVID-19 clinical trials and many existing non-COVID-19 studies either being temporarily paused
(whether that is a complete pause or pause in some activities) and/or adapting their processes. Trial managers have
played a key role in decision-making, undertaking risk assessments and adapting trial processes, working closely
with other members of the research team. This article presents some of the ways in which trial management
processes have been altered and the key role that trial managers have played. It has been born out of discussions
between trial managers in the UK who are members of the UK Trial Managers’ Network (UKTMN), a national
network of trial management professionals managing non-commercial trials.
In these unprecedented times, clinical trials have faced many uncertainties and broad-ranging challenges
encompassing a range of activities including prioritising patient safety amidst the pandemic, consenting and
recruiting new participants into trials, data collection and management and intervention delivery. In many cases,
recruitment has been paused whilst mitigations have been put in place to continue data collection. Innovative
solutions have been implemented to ensure we continue, where possible, to deliver high-quality clinical trials.
Technology has provided many solutions to these challenges, and trial managers have adapted to new ways of
working whilst continuing to deliver their clinical trials. Trial management groups are now faced with new
uncertainties around re-starting clinical trials, and it is unclear currently how this will go, though working together
with sponsors, funders and site teams is clearly a priority.
Clinical trial teams have worked together to ensure their trials have adapted quickly whilst ensuring participant
safety is given utmost importance. There are clear examples where the trial community have come together to
share experiences and expertise, and this should continue in the future to ensure the innovative practices
developed become embedded in the design and conduct of clinical trials in the future.
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Background
On 11 March 2020, the World Health Organization
(WHO) declared the outbreak of the COVID-19 pan-
demic [1]. Across the globe, countries implemented a
variety of restrictions to people’s everyday lives which
have included, country-wide lockdowns, social distan-
cing and, for many where it is possible to do so, working
from home. The impacts on clinical research have been
significant. Many researchers around the world have
acted quickly, designing and conducting new clinical tri-
als and research studies to obtain valuable evidence on
the virus and impact upon national and international
healthcare policies. Upon checking the UK’s Health Re-
search Authority (HRA) website for ethically approved
COVID-19 research on 4 June 2020, 142 studies had
been approved since 24 February 2020 [2], of which 49
have been classified as an urgent public health COVID-
19 study [3]. All of this has been done whilst many
people adapted to working from home whilst, in many
cases, juggling caring and home schooling responsibil-
ities. In addition to the rapid establishment of studies in-
vestigating the virus itself, there has been a significant
impact upon existing research studies and clinical trials.
In the UK, the largest funder of clinical research, the Na-
tional Institute for Health Research (NIHR), issued guid-
ance enabling clinical and academic healthcare
professionals who were working on existing non-COVID
studies within the NIHR portfolio, to support the NHS
by returning to clinical care duties [4]. In addition, the
Clinical Research Network (CRN) paused set-up of any
new or ongoing studies at sites, unless a national priority
for urgent public health research into COVID-19 [5].
Other agencies such as the European Medicines Agency
(EMA) also issued guidance on the management of clin-
ical trials during the pandemic [6]. This led to research
teams and sponsors urgently revising risk assessments to
consider the implications and impact on their clinical
trials. Following the release of these recommendations,
trial management groups (TMGs) were tasked with con-
sidering the implications upon pausing some or all as-
pects of studies, particularly if such a pause could
impact upon the care or safety of trial participants. Trial
management staff, working closely with Chief Investiga-
tors and other members of the immediate research team,
have been at the heart of leading discussions about the
impact of COVID-19 on their trials.
The UK Trial Managers’ Network (UKTMN) is a na-
tional network of around 800 trial management profes-
sionals, responsible for the day-to-day running of clinical
trials and other large research studies. Through discus-
sions in the UKTMN executive group, UKTMN mem-
bership via social media and online networking events
and wider experiences of trial managers amongst some
Clinical Trials Units (CTUs), this article presents some
of the challenges trials have faced and discusses some of
the innovative solutions that have been implemented in
order for trials to continue in the future, beyond the
pandemic. We specifically focus on the impact to non-
COVID-19 studies, rather than studies that have been
designed to focus on COVID-19 itself. At the time of
writing, we are not aware of other articles that consider
the implications on trial management during the
COVID-19 pandemic.
Problems and solutions
Trial recruitment and consent
Many trials have been paused to recruitment due to lack
of site research staff and the need to minimise face-to-
face contact with participants and potential participants
[4]. Some studies which have continued have seen a sig-
nificant reduction in their recruitment figures. A hybrid
model has been adopted in some cases, in keeping with
a proportionate approach to risk assessment, ensuring
each study is considered on an individual basis. One ex-
ample of this is a trial whereby the sponsor approved re-
cruitment to continue in circumstances where potential
participants had already been approached for participa-
tion, but had not yet provided postal consent, a process
which was already embedded within the consent path-
way [7]. A further example is of a trial conducted in the
Emergency Department (ED), where after a patient’s ini-
tial attendance in ED, all subsequent activities were con-
ducted online [8]. Other ways of communicating with
potential participants are also being explored; a trial in
patients with aortic stenosis is currently considering
plans to implement a process for using video-
conferencing with patients in order to undertake the
consent process remotely [9].
Obtaining informed consent for participation in a clin-
ical trial is a regulatory and ICH-GCP (Good Clinical
Practice) requirement [10]; this is commonly performed
in person where participants are asked to complete and
sign a paper consent form. However, whilst the use of
electronic informed consent is increasing, in our experi-
ence, it is still relatively uncommon. During this pan-
demic, some trials have utilised electronic consent
methods in order to continue trial recruitment whilst
minimising face-to-face contact with potential partici-
pants. These systems have been set-up quickly, often
with support from specialist programmers. In some cir-
cumstances, they have been used as an alternative to
paper consent, though still used in the context of a face-
to-face setting. Whilst this reduces the amount of paper
handling and arguably provides a more streamlined effi-
cient approach to consent in trials, electronic consent
could be most useful when truly “online” and not reliant
upon site staff providing participants with a smart device
to complete the electronic consent form. We anticipate
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that more trials in the future will develop electronic con-
sent systems, though careful consideration needs to be
given on a trial-by-trial basis particularly considering the
demographics of the study population, ensuring a pro-
portionate approach, and adherence with guidance pro-
vided by the HRA and Medicines for Healthcare
Regulatory Authority (MHRA) [11]. Using consistent
methods to record an electronic signature and ensuring
research staff gain experience in taking consent in this
way will be important.
Communication with site staff and other stakeholders
Regular communication with site staff is a key aspect
of trial management [12, 13]. Though recruitment in
many trials is paused, communication continues to be
crucial. For TMGs to make ongoing decisions about
changes to a trial, whether that be pausing/re-starting
or a change in trial process, input from site staff be-
fore decisions are finalised is vital. Principal Investiga-
tors and research nurses at sites offer valuable
perspectives into what is happening “on the ground”
and their absence in decision-making could result in
unintended consequences for the trial. Their input
into approaching trials holistically is crucial since to
consider one element of a trial alone, e.g. recruitment
or retention, could have a negative impact upon other
areas of the trial. Trial managers have been required
to test communication styles with sites, working with
sites to ensure they use the best communication
method for them (which may differ between sites).
Additionally, it has been necessary in some trials to
ascertain which site staff, if any, have the capacity to
undertake any trial-related activity. This has ensured
that the right communication is targeted to the right
people at the right time [14, 15].
In addition to communicating with site staff, trial
managers are also in close communication with trial
funders and sponsors. Some trial managers based in
CTUs, who are working on multiple trials, report that a
significant challenge has been communicating with mul-
tiple sponsors, all of whom may interpret guidance dif-
ferently and stipulate different requirements for risk
assessment, reporting and considering restarting trials.
Others have mitigated this by proposing processes dir-
ectly to sponsors. A substantial amount of time has been
spent by many trial managers in completing documenta-
tion, such as risk-assessments, contingency plans, ques-
tionnaires and reports for a variety of stakeholders, e.g.
funders, sponsors, Trial Steering Committees (TSCs)
and Data Monitoring Committees (DMCs). A stream-
lined approach to reporting would be welcomed and
allow trial managers to focus their time on other trial-
related activities.
Intervention delivery
Clinical trial interventions are broad-ranging, and a key
aspect of adapting the trial risk assessment during the
pandemic has been whether the intervention can still be
delivered to participants safely. It has been paramount
that TMGs have carefully considered the safest option(s)
for intervention delivery; in some cases, it may have
been safer to stop the intervention entirely, and in
others, finding a mechanism to deliver the intervention
safely has been implemented. For example, in some tri-
als, it has been deemed safe to deliver study medication
directly to the participant, without the requirement for a
face-to-face visit [16]. In other trials, trial managers re-
port participants stopping trial medications due to
COVID-19 concerns; however, many were prepared to
continue with remote follow-up. Other types of inter-
ventions may be delivered alongside routine clinical
practice, for example, surgical interventions. Since much
routine surgery has been postponed due to the pan-
demic, this has clearly impacted upon participants being
unable to have their trial intervention and thus overall
trial timelines. Trials that have a qualitative component
or where the intervention is, for example, a therapy ses-
sion (individual or group-based) may be able to be con-
ducted remotely via video-conferencing.
Data collection
Though in many cases trial recruitment has either
paused or reduced considerably, in some trials, it has
been possible to continue to collect data (for those
already recruited into the trial or for those trials who
have completed recruitment and are now in follow-up).
In some instances, where data collection is largely based
upon utilising data from existing clinical records, some
processes have been unaltered, though there has been an
impact upon data entry timelines. For some trials, data
entry and data query resolution is being undertaken by
trial managers, though this has presented logistical chal-
lenges whilst working at home. In other trials where data
is largely participant-reported, questionnaire completion
has shifted from postal questionnaires to telephone or
online data collection. Each approach has challenges: for
example, the time taken to collect data by telephone and
potential issues in collecting sensitive and/or clinical in-
formation over the telephone. Converting to online data
collection may involve additional programming time to
build the functionality into a trial database and will re-
quire participants to have provided an email address or
mobile phone number. These changes have perhaps
been easier to implement in departments where online
data collection had been used or explored previously,
but could be challenging and not necessarily a “quick
fix” when this option had previously not been explored
before. Attention has also been given to collecting data
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from other sources, such as biological samples. For ex-
ample, a trial investigating incentives for smoking cessa-
tion in pregnancy had been designed to collect saliva
samples at face-to-face clinic visits; a substantial amend-
ment has been approved in order to send the sample kits
directly to the participant’s home along with an envelope
to return this [17].
Trial managers reported undertaking a risk assessment
when considering data collection, many focussing only
on collection of critical data such as primary outcome
and safety data. The implications of any secondary data
not collected should be agreed within the TMG and dis-
cussed with oversight committees. In other circum-
stances, some trials in set-up are adding in additional
data items to their data collection tools to collect clinical
data relating to COVID-19, though it is recognised this
should be done in a streamlined way, utilising a core
outcome set where possible. Although only data that is
used for outcomes should be collected, we recognise this
is not always the case, with additional non-critical data
commonly being collected. This has been confirmed by
the recently published DataCat project which concluded
that a substantial amount of data collection is not re-
lated to trial outcomes [18]. In trials that have altered
their data collection processes and methods, initial feed-
back suggests participants have responded favourably,
though in many cases it is too early to formally evaluate
the impact upon participant retention. However, this
may present an opportunity for methodological work to
assess the impact of revised data collection pathways
and, for example, shorter questionnaires.
In addition to considerations from a data collection
perspective, the impact upon analysis of trial data is im-
portant to consider. It has been crucial that trial man-
agers have worked closely with trial statisticians and
health economists, in addition to other members of the
TMG, whilst considering this. For example, analysis
plans may need to be adapted to accommodate changes
such as timing of data collection and the way in which
data is being collected, alongside the wider implications
of the pandemic on trial outcomes. For example, in a
trial of a drug treatment for patients with chronic ob-
structive pulmonary disease (COPD), the team anticipate
that the exacerbation rate may be much lower since par-
ticipants have been shielding following the UK Govern-
ment’s guidance [16].
Re-starting
Although currently recruitment to many trials has been
temporarily paused, the NIHR has recently issued guid-
ance on re-starting trials, also relevant for studies funded
by UK Research and Innovation (UKRI) [19]. The Re-
start Framework outlines twelve guiding principles to
apply when considering re-starting clinical trials. Trial
sponsors, Chief Investigators, trial managers and TMGs
are currently considering how to apply the guidance to
their trials and whether indeed their trials are still viable
to continue. Some trials are considering different ap-
proaches to communicating with sites, such as asking
key site staff to complete a short survey on whether they
are ready to restart. Others have developed a traffic-light
system to consider re-start, and some CTUs are consid-
ering how best to implement a streamlined approach to
their portfolio of trials. There are many uncertainties in
restarting clinical trials, and it is too soon to properly as-
sess the issues. Some trial managers have reported con-
flicting opinions with respect to restart based upon the
role of the reporter. For example, Principal Investigators
report that the site is ready to restart trial activities,
whereas research nurses report lack of capacity to sup-
port these studies, since they are continuing to prioritise
COVID-19 public health priority studies or being tem-
porarily redeployed to other clinical duties. It is, of
course, important that trial teams work in close collab-
oration with funding bodies, sponsors and NHS partners
to ensure a streamlined consistent approach to restart
wherever possible. From a longer-term perspective,
whilst it is apparent that many studies will require ex-
tensions to funding contracts, due to a pause in activity,
it is unclear how many studies will require additional
funding and research teams welcome a sympathetic ap-
proach to this from funders.
Training
It is a regulatory and ICH-GCP requirement that all staff
who work on a clinical trial should be trained to do so
[10]. Training should incorporate relevant good clinical
practice training and trial-specific training. In many in-
stances, trial-specific training is provided face-to-face,
e.g. at a site initiation visit. However, many academic in-
stitutions currently have travel and financial restrictions
in place, potentially for the foreseeable future, and thus,
trial managers are devising alternative methods to pro-
vide training. This will also reduce unnecessary footfall
in the hospital setting. Whilst the opportunities for uti-
lising technology for training and other meetings existed
prior to the pandemic, many research teams continued
to utilise traditional approaches, perhaps since this is
what they and the site staff they were training were more
familiar with. The pandemic has forced research teams
to consider new approaches and to implement these
quickly, surely a positive to be taken from this inter-
national crisis. These include providing remote training
by video conferencing facilities, provision of webinars
and adding short training videos to trial websites. This
provision is relevant to many trials: new trials that are in
the set-up phase, ongoing trials where new sites are be-
ing set-up, trials where site staff may have changed
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(either due to COVID-19 or for other reasons) and re-
starting trials where re-training may be necessary,
dependent upon the length of the pause, the stage of the
trial and where significant changes have been made to
trial processes as a result of COVID-19. COVID-19 trials
have already implemented online training. For example,
in the RECOVERY-RS trial [20], members of the re-
search team delivered online site initiation meetings at
regular timeslots over several weeks for any site who was
able to join. In addition, all training materials were pro-
vided via the trial website, rather than paper documenta-
tion. Though there are some studies that have evaluated
clinical trials training, there is a paucity of evidence with
respect to training programmes that may improve site
performance [21]. A SWAT embedded in a surgical trial
demonstrated that holding online initial contact meet-
ings with sites did not appear to adversely affect set-up
times, screening, recruitment or data collection [22]. De-
veloping and implementing new methodologies for
training provides opportunities for trial managers, wider
research teams and methodologists to evaluate training
methods and their potential impact on a range of areas,
for example participant recruitment and retention and
data quality. The opportunities that web-based interac-
tions enable are great and wide-ranging. Prior to the
pandemic, in our experiences, many meetings were ei-
ther conducted face-to-face (which can often lead to
great expense and time, particularly if travel is required)
or by tele-conference, which, though more efficient and
less costly, has the disadvantage of not having the face-
to-face human interaction. Video conferencing, which
now features in many of our day-to-day lives, offers
some human interaction whilst also being an efficient
and less expensive way of meeting.
Impact on trials in the future
The world still faces a huge amount of uncertainty in
light of COVID-19. It is impossible to predict the on-
going impact upon many aspects of everyday life, includ-
ing how clinical trials may be designed and managed in
the future. Processes to comply with regulatory and eth-
ical frameworks have been adapted in order to approve
new clinical trials and trial amendments at a speed pre-
viously unimagined. For example, the RECOVERY (Ran-
domised Evaluation of COVID-19 Therapy) Trial, which
aims to identify treatments that may be beneficial for
people hospitalised with suspected or confirmed
COVID-19, was set-up in only 9 days—never has this
been achieved before [23].
Whilst the pandemic has created many challenges and
a monumental effort from trial management teams who
have had to implement new procedures, processes and
amendments in a time critical period, there are lessons
that can be learnt in managing trials in the future. It is
well known that clinical trials can be complicated and
expensive and therefore efficiencies in trial design and
conduct are crucial [24, 25]. We are hopeful that the les-
sons learnt during these unprecedented times can be
carried forward to clinical trials in the future, though
clearly a measured approach is required in order to en-
sure participant safety and adherence with relevant eth-
ical and legislative requirements. Trials should aim to
explore, implement and evaluate new technologies and
innovations; utilise data routinely available from a range
of sources; and at least for the foreseeable future, aim to
minimise face-to-face contact with participants wherever
possible. The recently launched Good Clinical Trials
Collaborative [26], led by Professor Martin Landray at
the University of Oxford, which aims to review the prin-
ciples of randomised clinical trials and provide new
guidelines, is welcomed, and UKTMN encourages the
clinical trials community to get involved. Additionally,
the profile of clinical trials in the general public has been
raised during the pandemic. Many members of the
public may have participated in a COVID-19 clinical
trial or research study themselves, and the urgent need
for evidence-based medicine has been highlighted inter-
nationally in the media and by senior officials within
many governments.
Sharing best practice
The issues the clinical trial community are faced with
are unprecedented. Never before have clinical trial teams
had to work in such a way. We have all adapted new
ways of working and implemented new processes into
clinical trials. To enable efficient, high-quality trials that
provide evidence for important health issues in the fu-
ture, we must come together and work as one. Sharing
best practice, lessons learnt and innovative approaches
has never been more important. The current clinical
trial infrastructure within the UK enables this; the net-
work of 51 UKCRC-registered CTUs play a vital role in
the provision of high-quality, relevant methodological
expertise in the efficient design and conduct of clinical
trials. Our own network, UKTMN, has conducted sev-
eral online or social media events, to complement its
existing forums, to share best practices and innovative
ways of working for its 800 members. In addition, a
range of other networks and initiatives exist, including
the Trials Methodology Research Partnership (TMRP),
Trial Forge and the Health Research Board Trials Meth-
odology Research Network (HRB-TMRN) all of which
enable continued learning and added value to clinical
trials. Many of these groups have developed resources to
facilitate shared-learning available on their websites. By
working together, alongside sponsors, funding bodies
and NHS partners, to learn from one another, the UK is
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in a unique position to lead the way in designing and
conducting high-quality, highly efficient clinical trials.
Conclusion
The COVID-19 pandemic has resulted in huge changes
to the way in which clinical trials are conducted. A
cross-cutting theme throughout many of these changes
has been the rapid advancement of technology utilisa-
tion. All communication has been virtual with trial man-
agers utilising a range of platforms to hold important
discussions with trial management groups, independent
oversight committees, sites, sponsors, funders and, in
some cases, participants. In addition, many trials have
moved critical processes such as informed consent and
primary outcome data collection online.
Having so rapidly altered many trial processes during
earlier stages of the pandemic, trial management teams
now need to carefully consider how to approach re-
starting their trials. This will require careful planning
and a streamlined approach by all stakeholders working
harmoniously. There are opportunities for investigators
and trial management teams to implement alternative
approaches to designing and conducting clinical trials in
the future in order to both increase efficiencies and re-
duce costs, in addition to opportunities for evaluation of
these approaches by conducting methodological studies.
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